Similarly, in the PALOMA-3 trial, for both HR-positive and HER2-negative advanced breast cancer patients who had previously received endocrine therapies, palbociclib plus fulvestrant also resulted in a longer PFS than fulvestrant alone10. Here, ERBB2 is linked to breast carcinoma.